Latest Team Growth and Elevation Signifies Firm Commitment to Evidence-Based Care
SAN RAMON, CALIF., Oct. 19, 2022— CooperVision, a world leader in myopia control and management for children, has hired Kathryn Richdale, OD, PhD, Diplomate CCLRT, as part of ongoing research and development expansion. In her role as a Clinical Research Fellow, Richdale will work across multiple areas of CooperVision’s clinical affairs on projects related to European Union Medical Device Regulation and, most timely, the MiSight® 1 day post-approval studies now underway in China and the U.S. Under Dr. Richdale’s direction, the studies will complement CooperVision’s widely-cited international MiSight® 1 day study.
“Data from the MiSight® 1 day post-approval studies will help define the future of myopia control for millions of children, while simultaneously extending CooperVision’s leadership in the field,” said Dr. Richdale. “It’s a privilege to apply my experience as an eye care professional, researcher, and educator in a new capacity to advance scientific understanding and clinical action on the international stage.”
Dr. Richdale has decades of clinical and research expertise in myopia, presbyopia, and cornea/anterior segment disease management. Most recently an associate professor at the University of Houston College of Optometry, she has also held roles at the SUNY College of Optometry and The Ohio State University. She received her bachelor’s degree from the University of Notre Dame and her PhD, Doctor of Optometry degree, and Cornea and Contact Lens Advanced Practice Fellowship from The Ohio State University. Her peer-reviewed publications have grown the knowledge base that eye care professionals (ECPs) need for evidence-based practice.
In addition to this expansion, CooperVision’s R&D team has continued to advance. Paul Chamberlain, BSc (Hons) has recently been promoted to Senior Director of Research Programs and has been appointed to the CooperVision R&D senior leadership team. In recent years, he has been instrumental in the research behind MiSight® 1 day, leading the study analysis that would lay the foundation for FDA approval* in 2019 and garner industry acclaim with the American Academy of Optometry’s Garland W. Clay Award in 2021. His expanded role will now include presbyopia research oversight as well.
“CooperVision has invested in researching the toughest vision challenges for decades, notably myopia, foretelling the disease’s global impact and how innovative interventions can change children’s lives. You can see it in our research rigor, in our comprehensive myopia management portfolio, and in our growing team,” said Chamberlain. “Together, we continue to build an evidence base that ECPs can trust and apply in their practice. The growing prevalence and severity of childhood myopia demands it.”
# # #
*U.S. Indications for Use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters(spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.
Hannah Barry, Counselor, McDougall Communications
email@example.com or +1-585-645-8985